A Randomized Double-Blind Phase-2 Study of Anastrozole Plus Lonafarnib (SCH 66336) or Anastrozole Plus Placebo for the Treatment of Subjects With Advanced Breast Cancer
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 110
- 主要终点
- Progression-free survival (PFS)
研究概览
简要总结
Primary Objective(s):
- To compare the activity (progression-free survival [PFS]) of anastrozole in combination with lonafarnib to that of anastrozole in combination with placebo in subjects with hormone-sensitive ADVANCED breast cancer.
Secondary Objective(s):
- To determine the effects of anastrozole in combination with lonafarnib on objective response, duration of response, overall survival, and safety in subjects with advanced breast cancer. To assess the exposure and pharmacokinetics of lonafarnib and anastrozole in the subject population.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Postmenopausal women who have histologically-confirmed breast cancer with the following characteristics:
- •estrogen and/or progesterone receptor positive,
- •locally advanced disease
- •distant metastatic disease, stage 4
- •Subjects eligible for single-agent treatment with aromatase inhibitors for current disease.
- •Subjects taking biophosphonates are allowed if they begin bisphosphonate therapy AT LEAST two weeks prior to randomization.
- •Measurable disease (masses with clearly defined margins on radiological images and at least one diameter >=20 mm[>=10 mm if spiral CT]) or evaluable disease (masses with margins not clearly defined on radiological images or with no diameter >= 20 mm). Subjects with bone disease only are permitted if disease is evaluable.
- •ECOG Performance Status of 0 or
- •Sufficient bone marrow reserve.
- •Adequate hepatic and renal function: laboratory values within protocol requirements.
排除标准
- •Subjects who have received more than one regimen of cytotoxic chemotherapy for advanced disease.
- •Subjects with with CLINICALLY APPARENT brain metastases or extensive visceral disease, including extensive hepatic involvement or pulmonary lymphangitic spread of tumor.
- •Subjects with prior treatments with FTIs.
- •Subjects with a known or suspected hypersensitivity to any excipients in the lonafarnib formulation (Providone, Poloxamer 188, croscarmellose sodium, silicon dioxide, and magnesium stearate).
研究组 & 干预措施
Lonafarnib plus Anastrozole
Participants receive lonafarnib 200 mg orally (PO) twice per day (BID) beginning on Day 1 Cycle 1 and continuing until Progression of Disease, unacceptable toxicity, or other discontinuation criteria are met; and anastrozole 1 mg, PO, once per day (QD) for as long as the participant is receiving lonafarnib
干预措施: Lonafarnib (Drug)
Lonafarnib plus Anastrozole
Participants receive lonafarnib 200 mg orally (PO) twice per day (BID) beginning on Day 1 Cycle 1 and continuing until Progression of Disease, unacceptable toxicity, or other discontinuation criteria are met; and anastrozole 1 mg, PO, once per day (QD) for as long as the participant is receiving lonafarnib
干预措施: anastrozole (Drug)
Placebo plus Anastrozole
Participants receive placebo to lonafarnib PO BID beginning on Day 1 Cycle 1 until Progression of Disease, unacceptable toxicity, or other discontinuation criteria are met; and anastrozole, 1mg PO QD for as long as the participant is receiving placebo
干预措施: Placebo (Drug)
Placebo plus Anastrozole
Participants receive placebo to lonafarnib PO BID beginning on Day 1 Cycle 1 until Progression of Disease, unacceptable toxicity, or other discontinuation criteria are met; and anastrozole, 1mg PO QD for as long as the participant is receiving placebo
干预措施: anastrozole (Drug)
结局指标
主要结局
Progression-free survival (PFS)
时间窗: When approximately 70 subjects have progressed
次要结局
- To access the exposure and pk of lonafarnib and anastrazole in the subject population.(When approximately 70 subjects have progressed)
- Objective response rate (adjusted RECIST criteria), duration of response, and overall survival(When approximately 70 subjects have progressed)